TheLongevity Trap

She was sixty-two, and she had brought a folder. Inside it were three years of cholesterol results, each one a little higher than the last, and a printout from a website that estimated her chance of a heart attack. She had circled the number in pen.

Her LDL was in the 160s. Her blood pressure in my office was 132 over 80. She had never smoked. She did not have diabetes. She walked most mornings and she watched what she ate, and she was not overweight. She told me all of this quickly, the way people do when they have rehearsed it, and then she told me the thing she had actually come to say.

Her father had died of a heart attack. He had been fifty-two. He had gone out to shovel the driveway after a storm, and he had not come back in. She was nineteen at the time. She had been the one who found him.

"I am ten years older than he ever got to be," she said. "Every birthday since fifty-two has felt borrowed. I want to know if I have it."

I understood what she meant by "it." She did not mean high cholesterol. She already knew she had that. She meant the thing that had been building in her father's arteries for decades without anyone knowing, the thing that announced itself only once. She wanted to know whether it was already in her.

I have watched this play out in my office more times than I can count. She wanted to know, and she was afraid to know. If the answer was yes, she would have to live with it. If the answer was no, she was not sure she would believe it. For forty-three years she had carried a quiet arithmetic: he died at fifty-two, and I am his daughter. Passing his age had not quieted it. It had only made her feel she was living on time she had not been promised. A test result was going to argue with that arithmetic, one way or the other.

She had also been reading. She had seen advertisements for full-body scans, for blood tests that promised to find disease years early, for clinics that would measure her "biological age." She asked me which of those she should do. She wanted to live longer than her father had. That, in the end, was the whole question.

I told her that none of those was where I would start. I told her I would start with one test, a simple one, and that it was the most useful test I know for a woman exactly like her.

· · ·

The recommendation

I will say it plainly, because the rest of this chapter depends on it.

I recommend a CT calcium score for adults roughly forty to seventy-five who have no symptoms and no known heart disease, whose ten-year risk of a heart attack or stroke falls in the borderline or intermediate range, and who are unsure whether to start a statin. A family history like hers is one of the clearest reasons to ask for one. The guidelines treat a heart attack or other atherosclerotic disease in a father or brother before fifty-five, or a mother or sister before sixty-five, as premature family history, and they count it as a formal risk-enhancing factor. Her father, dead at fifty-two, meets that definition. That alone pushes toward treatment. The scan tells us how hard to push.

I do not recommend it for everyone. If you already have heart disease, you do not need a scan to tell you so. If your risk is very low and you are young, the scan will almost always read zero and will not change anything. If your LDL is 190 or higher, or you have long-standing diabetes, you generally need treatment regardless of the score. And if you have chest pain or shortness of breath right now, this is not your test. You need a different evaluation, and you need it soon.

For the large group in the middle, people like the woman in my office, the calcium score is the best tool I have for answering the question she actually asked: is it already there?

This is a book about living longer

In the Introduction I defined longevity as two things together: lifespan, the years you live, and healthspan, the years you live well. A heart attack or stroke can take from both at once. This chapter tests the promise that matters most to my older readers, that a test can find a hidden danger early enough to prevent an early death.

Before I explain the test, I want to be clear about what this book is asking, because it is asking it in every chapter.

The word "longevity" has been taken over by people with something to sell. Supplements, scans, wearables, infusions, and tests are marketed as if each one adds years to your life. Most of them have never been shown to add a single day. That is the trap in the title. It is not that people want to live longer. Of course they do. So do I. The trap is believing that every measurement is a step toward that goal, when many measurements are only measurements.

So in each chapter I will ask the same question, and I will try to answer it honestly. Does this help you live longer? If it does, how? And how sure are we?

A test cannot make you live longer by itself. A number on a report has never lowered anyone's risk. A test can only help you live longer if it changes what you do, and if what you do then changes what happens to you. That is a chain with two links, and both of them have to hold.

The CT calcium score is a good test to begin with because the first link is strong and the second link is promising but not yet proven. I will show you both.

A short history of looking for calcium

Doctors have known for over a century that hardened arteries contain calcium. Pathologists could feel it at autopsy, gritty under the knife. For most of that century, though, there was no practical way to see it in a living, beating heart. The heart moves, and ordinary X-ray images of it are blurred.

That changed in the 1980s with a machine called the electron-beam CT scanner. Instead of rotating a heavy X-ray tube around the patient, it swept an electron beam across a target, fast enough to freeze the heart in a fraction of a second. For the first time, a radiologist could take sharp pictures of the coronary arteries without a catheter or dye, and the calcium in them showed up as bright white spots.

In 1990, a group led by Arthur Agatston and Warren Janowitz in Miami published a way to turn those bright spots into a number. Their method weighed the area of each calcified spot by how dense it was, and added the results together across all the coronary arteries. It is still called the Agatston score, and it is still the number on your report more than thirty-five years later. Electron-beam machines have since given way to the ordinary multidetector CT scanners found in most hospitals, but the scoring method stayed.

For years after that, the calcium score was something of an orphan. Some cardiologists loved it. Many were skeptical. It was sold directly to the public in storefront scanning centers in the 1990s, which did not help its reputation. What it needed was evidence from large populations, followed for years.

That evidence came, most importantly, from the Multi-Ethnic Study of Atherosclerosis, known as MESA. Starting in 2000, MESA enrolled about 6,800 men and women aged forty-five to eighty-four across six American communities, white, Black, Hispanic, and Chinese American, none of whom had known heart disease. Each one got a calcium scan, and then the researchers waited. The results, published over the following two decades, were consistent and striking. The calcium score predicted future heart attacks better than the standard risk factors alone, in every ethnic group, in women and in men. It also did something the risk calculators could not do well: it reclassified people. Many people the calculators called "intermediate" turned out to have no calcium at all and a very low event rate. Others turned out to have a great deal and a high one.

That body of evidence brought the test into the mainstream. In 2018, the American College of Cardiology and the American Heart Association published cholesterol guidelines that named the calcium score as a reasonable way to decide about statins in adults whose risk was intermediate, and in selected people whose risk was borderline, when the decision was uncertain. The 2019 guideline on primary prevention repeated that position.

In 2026, the two organizations, joined by nine other societies, replaced the 2018 cholesterol guideline with a new Guideline on the Management of Dyslipidemia, and the calcium score moved up. Where the 2018 guideline called it reasonable, the 2026 guideline says that in adults at intermediate risk, and selected adults at borderline risk, when the decision about cholesterol treatment remains uncertain, a calcium score should be used to decide whether to withhold, postpone, or start therapy. For the first time, it also ties the score to cholesterol goals. After decades on the margins, the test is now part of the standard of care, and the current guideline, as of this edition, is the 2026 one.

How the test works

The test itself is the least dramatic part of this story.

You lie on your back on the CT table. Small stickers are placed on your chest to track your heart rhythm, so the scanner can take its pictures at the same point in each heartbeat. You are asked to hold your breath for several seconds. There is no needle, no dye, and no IV. You do not need to change your medications. The scan is over in a few minutes, and most of the visit is the paperwork.

A computer then identifies the calcified spots in the coronary arteries, and a physician reviews them. The result is the Agatston score, a single number, usually with a breakdown by artery. Many reports also give a percentile, which compares your score with people of the same age, sex, and ethnicity in the MESA population. Many reports will also mention other things the scan happened to show in the lungs or chest. I will come back to those.

The radiation dose of a modern calcium scan is low, on the order of one millisievert, and often less. That is roughly what you receive from natural background radiation in a few months of ordinary life. It is not nothing, and it is one reason I do not recommend repeating the scan every year, but for a single test that can change a major decision it is a reasonable dose.

The cost is usually modest. In much of the United States a calcium scan costs somewhere around one hundred to two hundred dollars when paid in cash, and some centers charge less. Insurance coverage varies, and many plans still do not pay for it. Call before you schedule, and ask the cash price. It should not be a large number.

What the number means

The score is easiest to understand in a few broad ranges.

A score of zero. No calcium was found. This is the most powerful result the test can give. In MESA and other large studies, people with a score of zero had a very low rate of heart attacks over the next ten years, even when their cholesterol or blood pressure was elevated. For many people with a score of zero, it is reasonable to hold off on a statin and repeat the scan in about three to five years, which is the interval the American College of Cardiology's guideline tool suggests. The 2026 guideline itself does not set a fixed interval. That reassurance has conditions. It holds when major risk-enhancing factors are absent. In someone with diabetes, a smoking habit, or a premature family history like my patient's, a zero is weaker reassurance, and it should not by itself talk anyone out of treatment.

A score of 1 to 99. Some calcium is present. Plaque has started to form. This is not an emergency and it is not a diagnosis of heart disease in the sense most people fear. But it moves the needle toward treatment. In this range, if the score is below the 75th percentile, the 2026 guideline calls a moderate-intensity statin reasonable, aiming to lower LDL by roughly a third to a half and below 100.

A score of 100 or more, or at or above the 75th percentile for your age and sex. There is a meaningful amount of plaque. Here the 2026 guideline recommends cholesterol-lowering treatment, with a statin first, and sets a goal of an LDL below 70. The percentile matters as much as the raw number, especially for women and for younger people. A score of 50 in a woman in her early fifties may place her above the 75th percentile, and that should be taken seriously even though the number sounds small.

A score of 300 or more. This is a substantial plaque burden. In large studies, people in this range have a risk of heart attack and stroke similar to many people who have already had one. When I see a score in this range, I treat it as seriously as established disease: a statin, usually at a higher intensity, close attention to blood pressure and the rest, and a real conversation about aspirin. The 2026 guideline says it is reasonable at 300 or above to intensify treatment, adding other cholesterol drugs if needed, toward an LDL below 55, and it recommends that goal outright at 1,000 or above. A very high score does not by itself mean you need a stress test or a catheter. If you have no symptoms, it usually does not. What it means is that prevention is no longer optional.

One more point about the number. The score measures calcium, and calcium is a marker of plaque, not the whole of it. It tells you how much hardened plaque you have accumulated over a lifetime. It is a history book, not a weather report.

What the test cannot see

Every test has limits, and these matter.

It misses soft plaque. Plaque begins as a soft, fatty deposit in the artery wall. Calcium comes later, as part of the body's attempt to wall it off. A calcium scan sees only the calcified part. Soft, noncalcified plaque, which in some people is the more dangerous kind, is invisible to it. That is why a zero means low risk, not no risk.

A zero is less reassuring in some people. In smokers, a zero is weaker evidence, because smoking drives soft plaque and clotting in ways the scan does not capture. In people with diabetes, the same is true. In people with a premature family history, a father or brother with heart disease before fifty-five or a mother or sister before sixty-five, a zero is also weaker reassurance, because inherited risk, including inherited lipoprotein(a), can drive soft plaque the scan cannot see. And in younger people with that history, a zero may simply mean the calcium has not formed yet. For these groups, a zero should not talk you out of treatment you otherwise need.

It does not tell you about narrowing. The score tells you how much calcium there is, not whether any artery is blocked. A high score does not mean a blockage. A low score does not rule one out in someone with symptoms. If you have chest pain, the right test is usually a different one, such as a CT angiogram with dye, a stress test, or both.

It finds other things. Because the scan includes part of the lungs, it sometimes shows a small nodule or another finding unrelated to the heart. Most of these are harmless. Some lead to more scans, and a few lead to procedures. This is a real cost of the test, and you should know about it before you go in.

Statins can raise the score. This surprises people. Statins stabilize plaque, and part of that process can involve calcification. A rising score in someone on a statin does not necessarily mean the treatment is failing. This is one reason I rarely repeat the scan once someone is being treated.

How the score changes what I do

This is where the test earns its place. A calcium score that does not change a decision is a curiosity. One that does change a decision can matter.

Statins. The central question for someone like the woman in my office is whether to take a statin for the rest of her life. The risk calculators gave her a number in the gray zone, and the gray zone is exactly where reasonable doctors disagree and patients go back and forth for years. The calcium score settles that argument for most people. A zero, in someone without diabetes, smoking, or a premature family history, makes it reasonable to wait. A score of 100 or more, or a high percentile, makes a statin the clear choice. In between, the score tips the balance toward treatment, and it tells us how hard to push.

There is a second effect, and I see it every week. People who see their own calcium on a screen are more likely to take their medication and keep taking it. Several studies have shown higher statin use and better adherence after a positive scan. A pill prescribed for a risk score is abstract. A pill prescribed for something you can see in your own arteries is not.

Aspirin. Aspirin for preventing a first heart attack is a closer call than it used to be, and the calcium score can be one input into that decision. I return to aspirin in Chapter Eight. Do not start aspirin on your own because of a scan.

Everything else. A high score also changes the tone of everything else. Blood pressure targets get firmer. Exercise and diet stop being suggestions. If you smoke, the conversation about quitting gets very direct. The score does not change what good prevention is. It changes how seriously a person takes it.

For the younger reader

A man of forty came to see me because his older brother had needed a stent at forty-six. He wanted a calcium score, and he wanted it that afternoon. I understood. When a brother or sister has heart disease that young, the rest of the family starts counting.

I ordered the test, but only after we talked about what it could and could not tell him. At forty, most people have no calcium at all, even many who will have trouble later, because calcium is a late sign of plaque. So a zero at his age is less reassuring than a zero at sixty. It means not yet, not never. On the other hand, any calcium at all in a person under fifty deserves to be taken seriously. In a long study that followed young adults into middle age, even a small score in the late thirties and forties went with a higher chance of heart trouble over the next decade.

His score was zero. We did not stop there. We checked his Lp(a), which I describe in Chapter Eight, along with his blood pressure and cholesterol, and we agreed to look again in some years rather than call it settled. If you are under forty with a strong family history, the place to start is not the scan. It is the cholesterol test, the blood pressure cuff, and an honest conversation about your family.

So does it help you live longer?

Here is where I owe you honesty, because this is the question the book is built on.

I believe the calcium score helps people live longer. I believe it because of what I have seen and because of how the evidence fits together. But belief is not proof, and I want you to know exactly where the line is.

Here is what is established. Statins lower the risk of heart attack, stroke, and death from heart disease in people at increased risk. That has been shown in large randomized trials involving many tens of thousands of people, over decades. The calcium score identifies who is at increased risk better than the risk calculators alone do. It also identifies who is at low enough risk to skip a lifetime of medication. So the logic is straightforward: a better way of choosing who gets a proven treatment should mean better outcomes.

Here is what is not established. No randomized trial has yet shown that screening people with a calcium score, and treating them according to the result, lowers the death rate.

The closest we have come is a large Danish trial called DANCAVAS, published in 2022. It invited about 45,000 men aged sixty-five to seventy-four, and roughly 16,000 of them were offered a screening package that included a calcium score, along with checks for aortic aneurysm, peripheral artery disease, and high blood pressure. After a little more than five years, the death rate in the screened group was about five percent lower than in the comparison group, but the result fell just short of statistical significance. Only about two-thirds of the invited men actually came in, which diluted the effect, and the study included only men. When the researchers looked at those who did attend, the results were more encouraging, but that kind of analysis is less reliable.

A Dutch trial called ROBINSCA has been comparing calcium scoring with standard risk scoring in tens of thousands of adults. Its early reports show that the calcium score sorted people differently and led to more treatment for those at higher risk. Its final results on heart attacks and deaths are what we need, and I am waiting for them.

A related trial, SCOT-HEART in Scotland, studied people who already had chest pain, not people without symptoms. Adding a CT scan of the coronary arteries, with dye, to their care led to fewer deaths from heart disease and heart attacks over five years, apparently because doctors who saw plaque started more preventive treatment. It is a different test in a different population, but it supports the idea at the center of this chapter: seeing the plaque changes treatment, and the treatment changes outcomes.

So the honest summary is this. The calcium score is a promise. It is a strong one, built on solid evidence about prediction and solid evidence about statins. The final link, a trial showing that people screened this way live longer, is not yet in hand. More data is necessary, and some of it is coming.

I am comfortable recommending the test while we wait, for one reason: in the group I recommended it for, it is cheap, quick, low in radiation, and it answers a question that otherwise gets answered by guessing. Many of the tests in this book are expensive, unproven, and answer no question that changes what you would do. The calcium score is not one of them.

Why this is not the longevity trap

I want to draw a line between this test and the ones that crowd the advertisements.

The trap is a test that measures something without telling you what to do about it, or a test whose answer changes nothing. A biological age score, a full-body scan in a healthy person, a panel of a hundred blood markers in someone who feels well: these produce numbers, and the numbers produce worry or reassurance, but rarely a decision that has been shown to change how long anyone lives.

The calcium score is different in three ways. It is aimed at a specific question, whether you have coronary plaque. It is tied to a specific decision, whether to take a statin and how intensively. And that decision is tied to a treatment with strong evidence for preventing heart attacks and death. That is what a useful longevity test looks like. It is the standard I will hold every other test and supplement in this book to.

It is also a test with a natural limit. You do not need to repeat it every year, or chase the number up and down. For most people with a zero, a repeat scan in about three to five years is plenty. For people with calcium who are already being treated, there is usually no reason to repeat it at all. The point was the decision, and the decision has been made.

Back to my patient

I ordered the scan. She scheduled it for the following week, and then she rescheduled it twice.

When I asked her about that later, she was candid. She said that for forty-three years she had been able to tell herself two stories at once. In one story, she was her father's daughter and it was only a matter of time. In the other, she was careful, she walked, she ate well, and she was different from him. As long as she did not take the test, both stories could stay true. The scan was going to end one of them.

She came in on the third date. Her score was 140. For a woman of sixty-two, that placed her well above the 75th percentile. With her father's history already counting against her, there was no longer any gray zone.

She took the news more calmly than I expected. When I asked her how she felt, she said, "Relieved, I think. Isn't that strange?" It was not strange to me. She had been carrying a fear without a shape for most of her life, and now it had a shape and a number. A number was something she could do something about.

I started her on a statin. We talked about aspirin. At her age the guidelines lean against starting it to prevent a first heart attack, because the bleeding risk catches up with the benefit, and we decided to hold off and let the statin do the work. We talked about her blood pressure, which had been creeping up for a few years, and about the walking she already did, which I told her to keep doing. Our goal was an LDL below 70. Within a few months, her LDL had come down by more than half and was there.

What I did not do was order more tests. She asked about a stress test, and about the full-body scan a friend had recommended. She had no symptoms, and neither test would have changed what we were doing. That was a harder conversation than the scan result. Having found something, she wanted to keep looking. I told her that the finding had done its job. It had told us to treat, and we were treating. The next step was not another picture. It was years of taking a pill that works.

She came back a year later. Her LDL was where we wanted it. Her blood pressure was better. She told me she had shoveled her own driveway that winter for the first time since her father died. She had stood at the end of it afterward, she said, and thought about him for a while. Then she had gone back inside.

She had already outlived him by ten years, and she knew that was not the same as being safe. She did not know, and I could not tell her, how much longer she would have. No test can promise that. What I could tell her was that she now knew what he never had, and that she was doing something about it in time. That is what a good test is for.

· · ·

What to do this week

1. Find your ten-year risk, and your family history. Write down whether a father or brother had heart disease before fifty-five, or a mother or sister before sixty-five. That counts. Then ask your doctor for your ten-year risk, or use the American Heart Association's online risk calculator with your most recent cholesterol and blood pressure numbers. Write the number down.

2. Decide whether you are in the middle. If your risk is borderline or intermediate, and especially if a parent or sibling had heart disease, ask your doctor whether a CT calcium score would help you decide about a statin.

3. Know when the scan is not for you. If you already have heart disease, have an LDL of 190 or higher, or have chest pain or shortness of breath now, skip the calcium score and talk to your doctor about the right evaluation.

4. Ask the price before you book. Call the imaging center and ask what the scan costs if insurance does not cover it. It should be a modest amount.

5. Decide in advance what you will do with each answer. Before the scan, talk through with your doctor what a zero would mean for you and what a high score would mean. A test is only worth taking if the answer will change something.

6. Do not start aspirin on your own. If your score is high, discuss aspirin with your doctor, with your bleeding risk on the table.

He was sixty-one, recently retired, and he had paid for a whole-body MRI "to get ahead of things." He said it with some pride. He had always been the one in his family who changed the smoke detector batteries and kept the receipts. He was not worried about anything in particular. That was the point. He wanted to look before there was a reason to.

The report was eleven pages. Nearly all of it was normal. At the end were three lines. A small spot on the right kidney, indeterminate. A small spot on the liver, probably benign, recommend follow-up. A nodule in the thyroid, recommend ultrasound.

He had read those three lines the night the report came, and then again at two in the morning, and then he had looked up each word. By the time he reached my office he had a theory about all three. He had not told his wife about the kidney, because the kidney was the one that frightened him, and saying it out loud would have made it real.

"Which one of these is going to kill me?" he asked.

What struck me was not the fear. It was how bewildered he was by it. He had done the careful thing. He had done it before anyone told him to. And the careful thing had handed him three problems he did not have a week earlier, with no way to put them down.

I have seen this in many people since. He had bought the scan to stop worrying, and it had given him something new to worry about. And yet, sitting across from me, part of him was already wondering whether a better scan, or another scan, would settle it. The thing that had caused the fear was the thing he wanted more of.

I told him we would sort out the three lines one at a time. I also told him something he did not want to hear yet: that the scan he had bought is not one I recommend, and that I would explain why once we had his answers.

· · ·

The verdict

I will put it plainly, as I did in the first chapter.

I do not recommend a whole-body MRI or whole-body CT scan for healthy people at average risk who have no symptoms. This is an EXAMINE topic, not a RECOMMEND one. There is no evidence that these scans help healthy people live longer, and there is good evidence that they generate findings that lead to more tests, more procedures, more cost, and more worry.

There is one group for whom whole-body MRI is part of the standard of care: people with certain inherited cancer syndromes, most clearly Li-Fraumeni syndrome, an inherited change in a gene called TP53 that carries a very high lifetime risk of many cancers. For them, an annual whole-body MRI is part of an established surveillance program, and I will come back to it, because it is the exception that explains the rule.

If you are not in a group like that, my advice is to skip the scan and spend the money and attention on the tests in this book that have earned their place.

Longevity is the question

Remember the definition from the Introduction: longevity means lifespan and healthspan together. The whole-body scan makes the promise my older readers want most, early detection of the thing that would cut life short. This chapter asks whether it keeps that promise, and what it costs in the healthy years in between.

A whole-body scan is the purest form of the longevity promise. It says: we will look at everything, find what is wrong before it hurts you, and you will live longer because of it. It is an appealing idea. I understand why people pay for it.

But remember the chain from the first chapter. For the calcium score, the first link is strong and the second is promising. For the whole-body scan, both links are weak. The scan finds a great many things, and most of them do not need doing anything about. For the few that do, we do not yet know that finding them this way, in healthy people, leads to longer lives. That is not a guess on my part. It is what the radiologists who read these scans say themselves.

A short history of looking everywhere

This is not a new idea. It has come around at least twice.

In the late 1990s and early 2000s, storefront centers across the United States began selling whole-body CT scans directly to the public. Some advertised on billboards and radio. The scans were fast and cheap, and they found things. They also exposed healthy people to a meaningful dose of radiation, and they generated a wave of follow-up tests. Major medical and radiology groups have long advised against whole-body CT for people without symptoms. Most of those storefront centers closed within a few years.

The second wave is the one you see now. It uses MRI instead of CT, which removes the radiation. It is sold as a premium experience, often in elegant clinics, with an app, a results review, and a membership. Several companies offer it. Prenuvo is probably the best known. Ezra, which was acquired by the testing company Function Health in 2025, is another. There are others, and there will be more by the time you read this. I mention these names only as examples of a category, not as a judgment of any one company over another.

The technology has improved enormously. MRI scanners are faster, and software, including artificial intelligence, helps read the images. A whole-body scan that once took well over an hour can now be done, in some versions, in under half an hour. What has not changed is the basic question. Does looking at everything in a healthy person help that person live longer?

How the scan works

A whole-body MRI uses a strong magnetic field and radio waves to produce detailed images of the soft tissues. You lie in the scanner, usually for somewhere between twenty minutes and an hour depending on the package, and the machine images the body in sections, usually from the head to the pelvis or upper thighs. Most screening scans are done without contrast dye. There is no radiation.

That last point matters, and it is a real improvement over the CT scans of the earlier wave. But it comes with a trade. A diagnostic MRI that your doctor orders is aimed at a specific question, and the protocol is built for that organ, often with contrast. A screening whole-body MRI is built to look at everything, quickly, without contrast. The Canadian Association of Radiologists made this point in a 2025 policy statement: because a whole-body screening MRI is generalized rather than optimized for any one organ, it has lower sensitivity and lower specificity than a targeted scan. In plain terms, it can miss things a dedicated scan would catch, and it can flag things a dedicated scan would clear.

A whole-body CT uses X-rays and takes only a few minutes. It is better than MRI for some things, such as the lungs, and worse for others. It also carries radiation, which I will come to.

What it costs

These scans are not covered by insurance, because there is no evidence that they improve health. The prices change often, so treat these as rough. As I write, a full whole-body scan generally costs about two thousand dollars or more, with shorter or basic scans for less and premium packages for considerably more. Many of these companies now sell memberships that bundle a yearly scan with blood tests.

The scan is also not the whole cost. The follow-up tests that a scan triggers are usually billed to your insurance or to you, and they can easily exceed the price of the scan itself. That cost is the part no one advertises.

What it finds

Here is the most important thing to understand about these scans. They find something in most people.

That is not a sign that most people are sick. It is a sign of how much ordinary variation there is inside a healthy body. Cysts in the kidneys and liver, small nodules in the thyroid and lungs, benign blood vessel clusters, small spots on the adrenal glands, wear in the spine, and many other findings are common, and they become more common with age. Most will never cause a single symptom.

The numbers bear this out. A systematic review of whole-body MRI in healthy people, published in 2019, found that about one in three had findings classified as critical or indeterminate, meaning they needed either action or further investigation to sort out. An earlier review in the BMJ, looking at MRI in apparently healthy adults, found that potentially serious incidental findings turned up in about four percent of brain and body scans, and that the number rose to about thirteen percent when findings of uncertain significance were counted.

The companies' own data tell a similar story. One company published an analysis of more than eighty thousand of its scans done in 2024 and 2025. It reported that sixty-one percent of people had findings of at least some potential clinical relevance, most of them labeled as worth discussing with a primary care doctor. About four and a half percent had a finding that warranted dedicated diagnostic follow-up, and about three in a thousand had something requiring urgent follow-up. The rate of findings needing follow-up rose steadily with age, from under two percent in the youngest adults to nearly fifteen percent in people over seventy-five.

And cancer? A 2025 meta-analysis of ten studies, covering about nine thousand people without symptoms, found a confirmed cancer in about one and a half percent of them. That is not nothing. Some of those cancers were surely worth finding. But the same review noted that most of the studies had a moderate to serious risk of bias, that the protocols were not standardized, that incidental findings were frequent, and that there were no long-term outcome or cost-effectiveness data.

Notice what that last point means. We know these scans find cancers. We do not know how many of those cancers would have caused harm, how many would have been found in time anyway, and whether the people in whom they were found lived longer as a result.

Incidentalomas and false positives

Radiologists have a word for the spot that turns up on a scan done for some other reason: an incidentaloma. The word is half a joke, but the problem is real.

An incidentaloma is not necessarily a false positive. The spot is really there. The question is whether it matters. And the scan, by itself, often cannot say. A small kidney spot can be a cyst, a benign growth, or, rarely, an early cancer. A small liver spot can be a cluster of blood vessels or something worse. To tell them apart, you usually need another test.

Some findings turn out to be nothing at all, an artifact of the image or a shadow that looked like a lesion. Those are true false positives. The 2019 review found that, in the studies that reported them, false positives were common, though the estimates varied enormously. It also found that none of the studies had followed people for more than five years to confirm that a clean scan was really clean. We do not know, with any precision, how many things these scans miss.

There is a deeper problem, which doctors call overdiagnosis. This is not a mistaken finding. It is a real disease, even a real cancer, that would never have caused symptoms or shortened life if it had been left alone. When you find it, you treat it, because you cannot know it was harmless. The person bears the cost of the treatment and gets none of the benefit.

The clearest example comes from South Korea. In the early 2000s, thyroid ultrasound became a popular add-on to health checkups for people without symptoms. Over the next decade, the number of thyroid cancers diagnosed rose about fifteenfold, making it the most common cancer in the country. The death rate from thyroid cancer did not fall. Thousands of people had their thyroids removed, many of them living afterward on lifelong hormone pills, some with damage to the nerves of the voice or to the glands that control calcium, for cancers that were never going to hurt them. A whole-body scan looks at the thyroid, and at many other organs where the same thing can happen.

The cascade

This is what happened to my patient, and it is the part of the story most people do not see coming.

Each finding on a screening scan comes with a recommendation. Recommend follow-up. Recommend ultrasound. Recommend dedicated imaging. Each recommendation becomes an appointment, and each appointment can produce its own findings. Doctors call this the cascade.

For him, the three lines at the bottom of the report led to a CT scan with contrast dye for the kidney and the liver, an ultrasound of the thyroid, a visit to a urologist, and a repeat CT three months later to make sure the kidney spot had not changed. None of it found anything that needed treatment. It took four months. It included two CT scans, which meant two doses of the radiation he had chosen MRI to avoid, and two doses of contrast dye. It cost far more than the scan.

His cascade ended well. Some do not. A biopsy can bleed or cause infection. A surgery for a spot that turns out to be benign carries all the risks of surgery and none of the benefit. These harms are uncommon in any one person. Across hundreds of thousands of scans, they add up.

The American College of Radiology named exactly this concern in its 2023 statement on screening whole-body MRI. It said it is concerned that such scans will identify numerous nonspecific findings that will not ultimately improve patients' health but will result in unnecessary follow-up testing and procedures, as well as significant expense.

Radiation, for CT

Whole-body MRI does not use radiation. Whole-body CT does, and so do many of the follow-up tests that MRI findings lead to.

A CT scan delivers much more radiation than an ordinary X-ray. The dose from a whole-body CT is several times higher than the dose from the calcium score in Chapter One, and roughly comparable to several years of natural background radiation. For a single scan that answers a real medical question, that is an easy trade. For a scan done on a healthy person with no question to answer, it is harder to justify. The FDA notes that the radiation from a CT scan may be associated with a very small increase in the chance of developing cancer later in life. A very small risk is worth taking for a clear benefit. It is not worth taking for no benefit at all, and it is certainly not worth repeating every year.

This is why I am more cautious about whole-body CT than whole-body MRI, and why I am cautious about annual scanning of any kind.

What the professional societies say

When the specialists who read these scans for a living are skeptical of them, it is worth listening.

The American College of Radiology, in an April 2023 statement, said that it does not believe there is sufficient evidence to justify recommending total-body screening for patients with no symptoms, risk factors, or family history suggesting underlying disease or serious injury. It added that, to date, there is no documented evidence that total-body screening is cost-efficient or effective in prolonging life. It also said it will continue to monitor the research, which is the right posture.

The Canadian Association of Radiologists, in a 2025 policy statement, went further. It said it opposes whole-body MRI as a screening tool in people without symptoms, outside specific evidence-based indications, and that there is no compelling evidence from high-quality studies that it improves long-term health, reduces illness or death, or leads to better health in the population.

As I said earlier, the major medical groups have found no evidence that whole-body scanning of people without symptoms does more good than harm.

The American College of Preventive Medicine has publicly voiced similar skepticism.

As far as I can find, the American College of Cardiology has not issued a statement on whole-body scanning, which makes sense, because it is not a heart test. The heart test that some of these companies add to their packages is the calcium score from Chapter One, which the cardiology guidelines do support for the right people. The most useful part of some whole-body packages is the one part that has its own evidence.

No major medical society in the United States recommends whole-body scanning for healthy people at average risk.

The exception that explains the rule

There is one group in which whole-body MRI has been shown to help, and it is worth understanding why.

People with Li-Fraumeni syndrome carry an inherited change in the TP53 gene. Their lifetime risk of cancer is very high, and the cancers can arise almost anywhere, often at young ages. For them, a surveillance program sometimes called the Toronto protocol, which includes a yearly whole-body MRI alongside a dedicated brain MRI, breast imaging, ultrasound, blood tests, and regular exams, is the standard of care. It is endorsed in cancer-predisposition guidelines from the American Association for Cancer Research, and national cancer guidelines have aligned with it.

In an early study of that protocol, people who chose surveillance had a five-year survival of about eighty-nine percent, compared with about sixty percent in those who did not. That was not a randomized trial, and it was small, but the difference was large and the tumors were found earlier and smaller.

Here is why it works there and not for most of us. When the chance of cancer is very high, most of what a scan finds is real and worth finding. When the chance is low, as in a healthy sixty-year-old with no family history, most of what a scan finds is noise, and the real findings are buried under the false alarms. The same scan, read by the same radiologist, has a very different value depending on who is lying in it.

If you have a family history of many cancers, cancers at unusually young ages, or a known inherited cancer gene, talk to your doctor about genetic counseling. That is the right door into whole-body surveillance, and it leads to a program built for your risk, not a consumer package.

For the younger reader

The people who ask me about whole-body scans are getting younger. One was a woman of thirty-four, a runner, with no symptoms and no unusual family history. A friend had bought a scan as a birthday present to herself, and the ads had found her too.

I asked what she hoped to learn. She said peace of mind. I told her that, at her age, peace of mind is the thing the scan is least likely to deliver. Serious hidden disease is rare at thirty-four. Small harmless findings are not. A spot on a kidney, a cyst in the liver, a shadow in the lung that is almost certainly nothing: these turn up in a good share of healthy people, and each one can lead to another scan, a specialist, and weeks of waiting to learn it was nothing all along. The younger you are, the more of what the scan finds is likely to be noise, because there is less real disease for it to find.

She decided to spend the money on running shoes and a home blood pressure cuff for her parents. I thought that was a fine trade. If you are young and healthy, the scan is not a gift to your future self. It is a lottery ticket that mostly pays out in worry.

So does it help you live longer?

Here is the honest answer.

There is no evidence that whole-body scanning of healthy, average-risk people extends life. No randomized trial has tested it. The studies we have show what the scans find, not what happens to the people afterward. The radiologists' own professional body says there is no documented evidence that it prolongs life. The meta-analyses say long-term outcome data are lacking.

That does not mean it could never help. Imaging is getting better. Artificial intelligence may make reads more consistent and cut the false alarms. The companies themselves are building large databases, and some say they plan to follow people over time to measure outcomes. If a well-designed study someday shows that people screened this way live longer, without being harmed by the cascade, I will change my view and say so.

So I would call it, at best, a promise that has not yet been kept. What we need are trials that follow people for years and count deaths, not just findings.

Until then, I would rather a healthy person put that money and attention toward things with proof behind them. Blood pressure control. Not smoking. Physical activity. The cancer screenings with strong evidence, such as colon, breast, cervical, and, for long-term smokers, low-dose lung CT. And, for the right people, the calcium score. Those are not glamorous. They are what actually keeps people alive.

Why this is the longevity trap

The whole-body scan is close to a perfect example of the trap this book is named for.

It offers a feeling of control. It produces a great deal of information. It is sold with the language of prevention and longevity. And it does not answer a specific question tied to a specific decision tied to a proven treatment, which is what a useful test does. Instead it answers every question at once, loosely, and hands the uncertainty back to you.

It also invites repetition. Many of these companies sell annual memberships, and a clean scan this year can feel like a reason to check again next year. A scan with a finding can feel like a reason to check more often. Either way, the scan becomes a habit rather than a decision.

If you have already had one, you have not done anything wrong. But you do not need to make it a yearly ritual. If you decide to have one, do it once, if at all, with your eyes open about what it may start.

Back to my patient

He came back a year later for the recheck the report had asked for. Nothing had changed. He laughed about it this time, which he had not done the year before.

The kidney spot had turned out to be a simple cyst. The thyroid nodule was small and smooth and needed nothing. The liver spot was a cluster of blood vessels, the kind many people carry their whole lives without knowing. When the last result had come back clean, months earlier, he had not looked relieved so much as tired. "I thought I was buying peace of mind," he had said. "I think I bought a hobby."

Now he told me the company had written to invite him back for another scan, at a returning-member price. He admitted he had thought about it longer than he expected to. Part of him still wanted the clean page, the whole body, nothing at the bottom. He knew it might not come out clean, and he knew what would follow if it did not. He had thrown the letter away, and then fished it out of the recycling, and then thrown it away again.

I asked him what had finally made the decision. He said it was the arithmetic of it. He had spent four months and a good deal of money proving that three things were nothing. He had not added a day to his life, and he had lost a fair number of nights. The pull toward another scan was real, but he had learned to recognize it as a pull, not a reason.

We spent the rest of the visit on the things that would matter. His blood pressure, which was a little high. His colon screening, which was overdue. His cholesterol, which was borderline, and the question, which belonged in Chapter One, of whether a calcium score would help him decide about a statin.

A friend from his old job had asked him whether the scan was worth it. "I'm going to tell him to go get his blood pressure checked," he said, "and spend the rest on a vacation."

· · ·

What to do this week

1. If you are considering a whole-body scan, ask one question first. What specific decision would the result change? If you cannot name one, you probably do not need the scan.

2. Check your family history for cancer. If close relatives had many cancers, cancers at young ages, or a known cancer gene, ask your doctor about genetic counseling. That, not a consumer scan, is the path to surveillance if you need it.

3. Get current on the screenings that have earned their place. Colon, breast, and cervical screening at the ages your doctor recommends, and low-dose lung CT if you have a long history of smoking.

4. Know your blood pressure and your heart risk. If your risk is borderline or intermediate, ask whether a calcium score would help you decide about a statin. See Chapter One.

5. If you have already had a whole-body scan with findings, bring the full report to your doctor. Ask which findings truly need follow-up and which can be watched or left alone. Not every "recommend follow-up" requires a new test.

6. Do not sign up for an annual scan membership unless your doctor has a specific reason for repeat imaging.